⌘K
Loading ticker…
As of 2026-08-24, Axogen, Inc. Common Stock (AXGN) has a 3-month relative strength percentile of 81 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 73. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.1%, relative volume 0.66×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AXGN is in a stage 2 uptrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.5% / 35.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
AXGN appears in 1 ETF as of Jun 2026: PSC at 0.17% weight, $4M notional.
Held by 60 ETFs · $212M across latest filings · largest weight 3.16% (HTEC).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.17% | $4M | +0.02 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AXGN Jan avg: 13.36% median: 8.49% win: 75% σ: 19.94% n: 4 2022-04-12 → 2026-07-31 | AXGN Feb avg: -0.69% median: 0.13% win: 50% σ: 11.92% n: 4 2022-04-12 → 2026-07-31 | AXGN Mar avg: -3.04% median: -1.57% win: 50% σ: 16.40% n: 4 2022-04-12 → 2026-07-31 | AXGN Apr avg: -1.02% median: -4.55% win: 40% σ: 19.43% n: 5 2022-04-12 → 2026-07-31 | AXGN May avg: -1.47% median: -5.76% win: 40% σ: 24.29% n: 5 2022-04-12 → 2026-07-31 | AXGN Jun avg: 2.95% median: 6.00% win: 60% σ: 11.95% n: 5 2022-04-12 → 2026-07-31 | AXGN Jul avg: 8.35% median: 13.80% win: 60% σ: 14.35% n: 5 2022-04-12 → 2026-07-31 | AXGN Aug avg: 11.52% median: 11.92% win: 75% σ: 32.91% n: 4 2022-04-12 → 2026-07-31 (current) | AXGN Sep avg: 6.06% median: 8.57% win: 75% σ: 19.61% n: 4 2022-04-12 → 2026-07-31 | AXGN Oct avg: -1.15% median: -2.17% win: 25% σ: 20.25% n: 4 2022-04-12 → 2026-07-31 | AXGN Nov avg: 24.58% median: 14.11% win: 50% σ: 36.26% n: 4 2022-04-12 → 2026-07-31 | AXGN Dec avg: 7.05% median: 9.26% win: 75% σ: 12.18% n: 4 2022-04-12 → 2026-07-31 |